Skip to main content
Top
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Study protocol

Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial

Authors: Fiona Gaughran, Daniel Stahl, Khalida Ismail, Zerrin Atakan, John Lally, Poonam Gardner-Sood, Anita Patel, Anthony David, David Hopkins, Bee Harries, Philippa Lowe, Diana Orr, Maurice Arbuthnot, Robin M Murray, Kathryn E Greenwood, Shubulade Smith

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Cardiovascular morbidity and mortality is increased in individuals with severe mental illnesses.
We set out to establish a multicentre, two arm, parallel cluster randomized controlled trial (RCT) of a health promotion intervention (HPI), IMPACT Therapy. The patient-tailored IMPACT Therapy aims to target one or more health behaviours from a pre-defined list that includes cannabis use; alcohol use; other substance use; cigarette smoking; exercise; diet and diabetic control, prioritising those identified as problematic by the patient, taking a motivational interviewing and CBT approach.

Methods

Impact therapy will be delivered by care coordinators in the community to the treatment group and will be compared to treatment as usual (TAU). The main hypothesis is that the addition of IMPACT Therapy (HPI) to TAU will be more effective than TAU alone in improving patients’ quality of life as measured by the Short Form-36, including mental health and physical health subscales on completion of the intervention at 12 months post randomisation. A subsidiary hypothesis will be that addition of IMPACT Therapy (HPI) will be more cost-effective than TAU alone in improving health in people with SMI 12 months from baseline. The IMPACT therapy patient groups’ improvement in quality of life, as well as its cost effectiveness, is hypothesised to be maintained at 15 months. Outcomes will be analyzed on an intention-to-treat (ITT) basis.

Discussion

The results of the trial will provide information about the effectiveness of the IMPACT therapy programme in supporting community mental health teams to address physical comorbidity in severe mental illness.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Hennekens CH, Hennekens AR, Hollar D, Casey DE: Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005, 150 (6): 1115-1121.CrossRefPubMed Hennekens CH, Hennekens AR, Hollar D, Casey DE: Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005, 150 (6): 1115-1121.CrossRefPubMed
2.
3.
go back to reference Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, Blow FC: Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009, 31 (6): 555-563.CrossRefPubMedPubMedCentral Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, Blow FC: Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009, 31 (6): 555-563.CrossRefPubMedPubMedCentral
4.
go back to reference Roshanaei-Moghaddam B, Katon W: Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009, 60 (2): 147-156.CrossRefPubMed Roshanaei-Moghaddam B, Katon W: Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009, 60 (2): 147-156.CrossRefPubMed
5.
go back to reference Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000, 177: 212-217.CrossRefPubMed Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000, 177: 212-217.CrossRefPubMed
6.
go back to reference Laursen TM: Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011, 131 (1–3): 101-104.CrossRefPubMed Laursen TM: Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011, 131 (1–3): 101-104.CrossRefPubMed
7.
go back to reference Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V: Mental disorders and cause-specific mortality. Br J Psychiatry. 2001, 179: 498-502.CrossRefPubMed Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V: Mental disorders and cause-specific mortality. Br J Psychiatry. 2001, 179: 498-502.CrossRefPubMed
8.
go back to reference Angst F, Stassen HH, Clayton PJ, Angst J: Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002, 68 (2–3): 167-181.CrossRefPubMed Angst F, Stassen HH, Clayton PJ, Angst J: Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002, 68 (2–3): 167-181.CrossRefPubMed
9.
go back to reference Osborn DJ, Levy G, Nazareth I, Petersen I, Islam A, King MB: Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the united kingdoms general practice research database. Arch Gen Psychiatry. 2007, 64 (2): 242-249.CrossRefPubMed Osborn DJ, Levy G, Nazareth I, Petersen I, Islam A, King MB: Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the united kingdoms general practice research database. Arch Gen Psychiatry. 2007, 64 (2): 242-249.CrossRefPubMed
10.
go back to reference Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007, 64 (10): 1123-1131.CrossRefPubMed Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007, 64 (10): 1123-1131.CrossRefPubMed
11.
go back to reference McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80 (1): 19-32.CrossRefPubMed McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80 (1): 19-32.CrossRefPubMed
12.
go back to reference De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006, 83 (1): 87-93.CrossRefPubMed De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006, 83 (1): 87-93.CrossRefPubMed
13.
go back to reference Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet. 2005, 366 (9491): 1059-1062.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet. 2005, 366 (9491): 1059-1062.CrossRefPubMed
14.
go back to reference Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007, 49 (4): 403-414.CrossRefPubMed Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007, 49 (4): 403-414.CrossRefPubMed
15.
go back to reference Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005, 165 (22): 2644-2650.CrossRefPubMed Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005, 165 (22): 2644-2650.CrossRefPubMed
16.
go back to reference Meyer JM, Stahl SM: The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009, 119 (1): 4-14.CrossRefPubMed Meyer JM, Stahl SM: The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009, 119 (1): 4-14.CrossRefPubMed
17.
go back to reference Correll CU, Frederickson AM, Kane JM, Manu P: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006, 67 (4): 575-583.CrossRefPubMed Correll CU, Frederickson AM, Kane JM, Manu P: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006, 67 (4): 575-583.CrossRefPubMed
18.
go back to reference Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I: Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008, 8 (84): 8-84. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I: Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008, 8 (84): 8-84.
19.
go back to reference Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 1: 1-93. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 1: 1-93.
20.
go back to reference Foley DL, Morley KI: Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011, 68 (6): 609-616.CrossRefPubMed Foley DL, Morley KI: Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011, 68 (6): 609-616.CrossRefPubMed
21.
go back to reference De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8 (2): 114-126.CrossRefPubMed De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8 (2): 114-126.CrossRefPubMed
22.
go back to reference Bobes J, Arango C, Garcia-Garcia M, Rejas J: Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010, 119 (1–3): 101-109.CrossRefPubMed Bobes J, Arango C, Garcia-Garcia M, Rejas J: Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010, 119 (1–3): 101-109.CrossRefPubMed
23.
go back to reference Vancampfort D, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, Peuskens J, De Hert M: Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res. 2010, 177 (3): 271-279.CrossRefPubMed Vancampfort D, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, Peuskens J, De Hert M: Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res. 2010, 177 (3): 271-279.CrossRefPubMed
24.
go back to reference Alvarez-Jimenez M, Martinez-Garcia O, Perez-Iglesias R, Ramirez ML, Vazquez-Barquero JL, Crespo-Facorro B: Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res. 2010, 116 (1): 16-19.CrossRefPubMed Alvarez-Jimenez M, Martinez-Garcia O, Perez-Iglesias R, Ramirez ML, Vazquez-Barquero JL, Crespo-Facorro B: Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res. 2010, 116 (1): 16-19.CrossRefPubMed
25.
go back to reference Lester HSD, Rafi I, Cooper SJ, Holt RIG: Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis on antipsychotic medication. 2012, London: Royal College of Psychiatrists Lester HSD, Rafi I, Cooper SJ, Holt RIG: Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis on antipsychotic medication. 2012, London: Royal College of Psychiatrists
26.
go back to reference Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005, 80 (1): 45-53.CrossRefPubMed Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005, 80 (1): 45-53.CrossRefPubMed
27.
go back to reference Bailey S, Gerada C, Lester H, Shiers D: The cardiovascular health of young people with severe mental illness: addressing an epidemic within an epidemic. Psychiatrist. 2012, 36 (10): 375-378.CrossRef Bailey S, Gerada C, Lester H, Shiers D: The cardiovascular health of young people with severe mental illness: addressing an epidemic within an epidemic. Psychiatrist. 2012, 36 (10): 375-378.CrossRef
28.
go back to reference Department of Health: On the state of the public health: Annual report of the Chief Medical Officer. 2003, London: Department of Health Department of Health: On the state of the public health: Annual report of the Chief Medical Officer. 2003, London: Department of Health
29.
go back to reference de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia research. 2005, 76 (2): 135-157.CrossRefPubMed de Leon J, Diaz FJ: A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia research. 2005, 76 (2): 135-157.CrossRefPubMed
30.
go back to reference de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM: Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995, 152 (3): 453-455.CrossRefPubMed de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM: Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995, 152 (3): 453-455.CrossRefPubMed
31.
go back to reference Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. Jama. 1990, 264 (19): 2511-2518.CrossRefPubMed Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. Jama. 1990, 264 (19): 2511-2518.CrossRefPubMed
32.
go back to reference Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, Farrell M, Murray RM: Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med. 2006, 36 (10): 1441-1446.CrossRefPubMed Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, Farrell M, Murray RM: Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med. 2006, 36 (10): 1441-1446.CrossRefPubMed
33.
go back to reference González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, Haidar MK, Vieta E, Arango C: Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull. 2011, 37 (3): 631-639.CrossRefPubMed González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, Haidar MK, Vieta E, Arango C: Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull. 2011, 37 (3): 631-639.CrossRefPubMed
34.
go back to reference Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007, 370 (9584): 319-328.CrossRefPubMed Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007, 370 (9584): 319-328.CrossRefPubMed
35.
go back to reference Grech A, Van Os J, Jones PB, Lewis SW, Murray RM: Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005, 20 (4): 349-353.CrossRefPubMed Grech A, Van Os J, Jones PB, Lewis SW, Murray RM: Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005, 20 (4): 349-353.CrossRefPubMed
36.
go back to reference Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008, 193 (5): 357-363.CrossRefPubMed Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008, 193 (5): 357-363.CrossRefPubMed
37.
go back to reference Linszen DH, Dingemans PM, Lenior ME: Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994, 51 (4): 273-279.CrossRefPubMed Linszen DH, Dingemans PM, Lenior ME: Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994, 51 (4): 273-279.CrossRefPubMed
38.
go back to reference Isaac M, Holloway F: Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol. 2005, 20 (3): 207-210.CrossRefPubMed Isaac M, Holloway F: Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Hum Psychopharmacol. 2005, 20 (3): 207-210.CrossRefPubMed
39.
go back to reference Haddock CK, Lando H, Klesges RC, Peterson AL, Scarinci IC: Modified tobacco use and lifestyle change in risk-reducing beliefs about smoking. Am J Prev Med. 2004, 27 (1): 35-41.CrossRefPubMed Haddock CK, Lando H, Klesges RC, Peterson AL, Scarinci IC: Modified tobacco use and lifestyle change in risk-reducing beliefs about smoking. Am J Prev Med. 2004, 27 (1): 35-41.CrossRefPubMed
40.
go back to reference Barrowclough C, Lobban F, Hatton C, Quinn J: An investigation of models of illness in carers of schizophrenia patients using the illness perception questionnaire. Br J Clin Psychol. 2001, 40 (Pt 4): 371-385.CrossRefPubMed Barrowclough C, Lobban F, Hatton C, Quinn J: An investigation of models of illness in carers of schizophrenia patients using the illness perception questionnaire. Br J Clin Psychol. 2001, 40 (Pt 4): 371-385.CrossRefPubMed
41.
go back to reference Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, Davies L, Dunn G, Eisner E, Lewis S, et al: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010, 341: c6325-CrossRefPubMedPubMedCentral Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, Davies L, Dunn G, Eisner E, Lewis S, et al: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010, 341: c6325-CrossRefPubMedPubMedCentral
42.
go back to reference Kathryn G, Shubulade S, Zerrin A: Impact - The Reference Guide: Improving Physical Health and Treating Substance Use in Mental Illness. 2011, London UK: South London and Maudsley NHS Foundation Trust Kathryn G, Shubulade S, Zerrin A: Impact - The Reference Guide: Improving Physical Health and Treating Substance Use in Mental Illness. 2011, London UK: South London and Maudsley NHS Foundation Trust
43.
go back to reference Stewart AL, Ware JE: Measuring Functioning and Well-being: The Medical Outcomes Study Approach. 1992, Duke University Press Stewart AL, Ware JE: Measuring Functioning and Well-being: The Medical Outcomes Study Approach. 1992, Duke University Press
44.
go back to reference Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. Jama. 2001, 285 (15): 1992-1995.CrossRefPubMed Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. Jama. 2001, 285 (15): 1992-1995.CrossRefPubMed
46.
go back to reference Greenwood Kathryn SS, Atakan Z: Impact - The Reference Guide: Improving Physical Health and Treating Substance Use in Mental Illness. 2011, London UK: South London and Maudsley NHS Foundation Trust Greenwood Kathryn SS, Atakan Z: Impact - The Reference Guide: Improving Physical Health and Treating Substance Use in Mental Illness. 2011, London UK: South London and Maudsley NHS Foundation Trust
47.
go back to reference Sobell L, Sobell M: Timeline Follow-Back. Measuring Alcohol Consumption. Edited by: Litten R, Allen J. 1992, Humana Press, 41-72.CrossRef Sobell L, Sobell M: Timeline Follow-Back. Measuring Alcohol Consumption. Edited by: Litten R, Allen J. 1992, Humana Press, 41-72.CrossRef
48.
go back to reference Fagerstrom KO, Schneider NG: Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire. J Behav Med. 1989, 12 (2): 159-182.CrossRefPubMed Fagerstrom KO, Schneider NG: Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire. J Behav Med. 1989, 12 (2): 159-182.CrossRefPubMed
49.
go back to reference Fagerstrom KO: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978, 3 (3–4): 235-241.CrossRefPubMed Fagerstrom KO: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978, 3 (3–4): 235-241.CrossRefPubMed
50.
go back to reference Saunders JB, Aasland OG, Babor TF, DeLaFuente JR, Grant M: Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction. 1993, 88: 617-629. Saunders JB, Aasland OG, Babor TF, DeLaFuente JR, Grant M: Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction. 1993, 88: 617-629.
51.
go back to reference Roe L, Strong C, Whiteside C, Neil A, Mant D: Dietary intervention in primary care: validity of the DINE method for diet assessment. Fam Pract. 1994, 11 (4): 375-381.CrossRefPubMed Roe L, Strong C, Whiteside C, Neil A, Mant D: Dietary intervention in primary care: validity of the DINE method for diet assessment. Fam Pract. 1994, 11 (4): 375-381.CrossRefPubMed
52.
go back to reference Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003, 35 (8): 1381-1395.CrossRefPubMed Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003, 35 (8): 1381-1395.CrossRefPubMed
53.
go back to reference Kay SR, Opler LA, Lindenmayer JP: The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989, 7: 59-67.PubMed Kay SR, Opler LA, Lindenmayer JP: The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989, 7: 59-67.PubMed
54.
go back to reference American Psychiatric Association: Multiaxial assessment. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revised). 2002, (DSM–IV–TR): APA American Psychiatric Association: Multiaxial assessment. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revised). 2002, (DSM–IV–TR): APA
55.
go back to reference Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389.CrossRefPubMed Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389.CrossRefPubMed
56.
go back to reference McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991 Aug, 48 (8): 764-770.CrossRefPubMed McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991 Aug, 48 (8): 764-770.CrossRefPubMed
57.
go back to reference Kemp R, Hayward P, Applewhaite G, Everitt B, David A: Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996, 312 (7027): 345-349.CrossRefPubMedPubMedCentral Kemp R, Hayward P, Applewhaite G, Everitt B, David A: Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996, 312 (7027): 345-349.CrossRefPubMedPubMedCentral
58.
go back to reference Day JC, Wood G, Dewey M, Bentall RP: A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995, 166 (5): 650-653.CrossRefPubMed Day JC, Wood G, Dewey M, Bentall RP: A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995, 166 (5): 650-653.CrossRefPubMed
59.
go back to reference Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B, Group ES: Client socio-demographic and service receipt inventory - European version : development of an instrument for international research: EPSILON Study 5. Br J Psychiatry. 2000, 177 (39): s28-s33.CrossRef Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B, Group ES: Client socio-demographic and service receipt inventory - European version : development of an instrument for international research: EPSILON Study 5. Br J Psychiatry. 2000, 177 (39): s28-s33.CrossRef
60.
go back to reference Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, et al: Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry. 2006, 189: 508-514.CrossRefPubMed Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, et al: Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry. 2006, 189: 508-514.CrossRefPubMed
61.
go back to reference Campbell MJ, Donner A, Klar N: Developments in cluster randomized trials and statistics in medicine. Stat Med. 2007, 26 (1): 2-19.CrossRefPubMed Campbell MJ, Donner A, Klar N: Developments in cluster randomized trials and statistics in medicine. Stat Med. 2007, 26 (1): 2-19.CrossRefPubMed
62.
go back to reference Roberts C, Roberts SA: Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials. 2005, 2 (2): 152-162.CrossRefPubMed Roberts C, Roberts SA: Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials. 2005, 2 (2): 152-162.CrossRefPubMed
63.
64.
go back to reference Shafer J: Analysis of Incomplete Multivariate Data. Series. 1997, New York: Chapman and HallCrossRef Shafer J: Analysis of Incomplete Multivariate Data. Series. 1997, New York: Chapman and HallCrossRef
65.
go back to reference Royston P: Multiple imputation of missing values: update. Stata J. 2005, 5 (2): 188-201. Royston P: Multiple imputation of missing values: update. Stata J. 2005, 5 (2): 188-201.
66.
go back to reference Shafer J: Analysis of Incomplete Multivariate Data. 1997, New York: Chapman and HallCrossRef Shafer J: Analysis of Incomplete Multivariate Data. 1997, New York: Chapman and HallCrossRef
67.
go back to reference van Buuren S: Multiple imputation of multilevel data. The Handbook of Advanced Multilevel Analysis(10). Edited by: Hox JJ, Roberts JK, Milton P. 2011, UK: Routledge, 173-196. van Buuren S: Multiple imputation of multilevel data. The Handbook of Advanced Multilevel Analysis(10). Edited by: Hox JJ, Roberts JK, Milton P. 2011, UK: Routledge, 173-196.
68.
go back to reference White IR, Horton NJ, Carpenter J, Pocock SJ: Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011, 7 (342): d40-CrossRef White IR, Horton NJ, Carpenter J, Pocock SJ: Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011, 7 (342): d40-CrossRef
69.
go back to reference Dunn G, Maracy M, Tomenson B: Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005, 14 (4): 369-395.CrossRefPubMed Dunn G, Maracy M, Tomenson B: Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005, 14 (4): 369-395.CrossRefPubMed
70.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21 (2): 271-292.CrossRefPubMed Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21 (2): 271-292.CrossRefPubMed
71.
go back to reference van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994, 3 (5): 309-319.CrossRefPubMed van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994, 3 (5): 309-319.CrossRefPubMed
73.
go back to reference Caemmerer J, Correll CU, Maayan L: Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012, 140 (1–3): 159-168.CrossRefPubMed Caemmerer J, Correll CU, Maayan L: Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012, 140 (1–3): 159-168.CrossRefPubMed
Metadata
Title
Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial
Authors
Fiona Gaughran
Daniel Stahl
Khalida Ismail
Zerrin Atakan
John Lally
Poonam Gardner-Sood
Anita Patel
Anthony David
David Hopkins
Bee Harries
Philippa Lowe
Diana Orr
Maurice Arbuthnot
Robin M Murray
Kathryn E Greenwood
Shubulade Smith
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-263

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue